Results 31 to 40 of about 148,910 (315)
Metformin and the intestine [PDF]
Diabetologia, 2008 To the Editor: The antihyperglycaemic effect of metformin is generally attributed to a decrease in hepatic glucose output, with some additional effects that increase peripheral glucose uptake and utilisation [1]. The intestine also makes an important contribution to the glucose-lowering effect of metformin, but this is often overlooked because of a ...
C J, Bailey +2 more
openaire +2 more sources
Metformin from mother to unborn child – Are there unwarranted effects?
EBioMedicine, 2018 For more than 40 years, metformin has been used before and during pregnancy. However, it is important to note that metformin can cross the placenta and circulate in the developing foetus.
Linh Nguyen +2 more
doaj +1 more source
Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy [PDF]
, 2014 Metformin is under evaluation as a potential anticancer agent. Expression of total and phospho(Thr172)-adenosine monophosphate-activated kinase-α (AMPKα and pAMPKα(Thr172) respectively), a main metformin target, was examined in radiotherapy treated ...
Johnson, Kerstie +7 more
core +1 more source
Intracerebroventricular Injection of Metformin Induces Anorexia in Rats [PDF]
Diabetes & Metabolism Journal, 2012 BackgroundMetformin, an oral biguanide insulin-sensitizing agent, is well known to decrease appetite. Although there is evidence that metformin could affect the brain directly, the exact mechanism is not yet known.MethodsTo evaluate whether metformin ...
Chang Koo Lee +5 more
doaj +1 more source
Journal of Pharmacological Sciences, 2021 Introduction: Heart failure is the final pathway for a wide spectrum of myocardial stress, including hypertension and myocardial infarction. However, the potential effects of metformin on cardiac hypertrophy are still unclear.
Yoichi Sunagawa +10 more
doaj +1 more source
Metformin Targets Foxo1 to Control Glucose Homeostasis
Biomolecules, 2021 Metformin is the first-line pharmacotherapy for type 2 diabetes mellitus (T2D). Metformin exerts its glucose-lowering effect primarily through decreasing hepatic glucose production (HGP).
Xiaoqin Guo +13 more
doaj +1 more source
JAMA, 2019 Metformin is the first-line pharmacologic treatment for type 2 diabetes and the most commonly prescribed drug for this condition worldwide, either alone or in combination with insulin or other glucose-lowering therapies. Metformin is a biguanide, a drug class of herbal origin that has been widely used to treat diabetes since the 1950s.1,2 Two other ...
James, Flory, Kasia, Lipska
openaire +3 more sources
The pharmacogenetics of metformin [PDF]
Diabetologia, 2017 Despite its widespread use as the first-line agent for the treatment of type 2 diabetes, it has become clear that metformin does not work optimally for everyone. Elucidating who are the likely metformin responders and non-responders is hampered by our limited knowledge of its precise molecular mechanism of action.
openaire +2 more sources
NeuroSci, 2022 In our previous study, metformin was able to promote nerve regeneration after sciatic nerve crushing in rats under diabetic conditions. However, a crush injury also has a strong ability to spontaneously recover.
Junxiong Ma +4 more
doaj +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2021 Thanida Tangjarusritaratorn,1 Watip Tangjittipokin,1,2 Tada Kunavisarut3 1Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 2Siriraj Center of Research Excellence in Diabetes and Obesity, Faculty of ...
Tangjarusritaratorn T +2 more
doaj